Exkivity (Mobocertinib)
- Medicine Name: Exkivity
- Generic Name: Mobocertinib
- Dosage Form & Strength: Capsules: 40 mg
- Manufactured By: Takeda Pharma Company Ltd
- Mobocertinib can be responsible for causing severe heart rate-corrected QT (QTc) prolongation, including Torsades de Pointes, which may be fatal. Assess QTc and electrolytes and correct abnormalities in potassium, sodium, calcium, and magnesium before initiating mobocertinib 40 mg.
- Monitor electrolytes and QTc periodically during treatment. Monitoring frequency needs to be increased in patients with risk factors for QTc prolongation, such as patients with congenital long QT syndrome, heart disease, or electrolyte abnormalities. Do not use concomitant medicines which are known to prolong the QTc interval.
- Mobocertinib can cause ILD/pneumonitis, which may be fatal. Monitor patients for new/worsening pulmonary symptoms indicative of ILD/pneumonitis. Promptly withhold therapy in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.
- Exkivity (mobocertinib) can cause cardiac toxicity resulting in heart failure which could be fatal. Monitor cardiac function, including assessment of left ventricular ejection fraction during therapy. Withhold, reduce the dose, or permanently discontinue Mobocertinib on behalf of severity.
- Exkivity can be responsible for causing diarrhea, which can be severe. Patients should start an antidiarrheal agent at first sign of diarrhea or increased bowel movement frequency and to increase fluid and electrolyte intake. Monitor electrolytes and withhold, reduce the dose or permanently discontinue exkivity 40 mg on behalf of severity.
- Depending on findings from animal studies and its mechanism of action, Mobocertinib can cause fetal harm if administered to a pregnant woman. Women should not breastfeed during treatment with Mobocertinib and for 7 days after the final dose.
What documents are required to import EXKIVITY to India?
EXKIVITY (Mobocertinib) Capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity (ID) Proof (issued by Govt of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is EXKIVITY available in India?
EXKIVITY (mobocertinib capsules) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of exkivity in India (Mumbai, Pune, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, and Bangalore etc.)
- Medicine Price.
- Finding Genuine and reliable source from USA, Canada, Europe and Australia
- Ensuring 100% transparency.
EXKIVITY can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of EXKIVITY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for mobocertinib capsules price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the EXKIVITY (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Exkivity®?
Mobocertinib is Generic Name for the trade name drug Exkivity®.
What is the Manufacturer Name of Exkivity®?
Exkivity® is manufactured by Takeda Pharmaceutical Company Limited.
Is Exkivity® approved by the FDA?
Yes, Exkivity® is approved by the FDA. Date of approval: September 15, 2021.
What is Exkivity®?
Exkivity® is a first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
What is the dosage and form of Exkivity® supplied?
Exkivity® is supplied as Capsules: 40 mg for oral administration.
What are the most common side effects due to Exkivity®?
Most common side effects due to Exkivity® include: rash, diarrhea, nausea, stomatitis, vomiting, fatigue, decreased appetite, paronychia, dry skin, and musculoskeletal pain.
How much does Mobocertinib cost in India?
The mobocertinib cost in India is reasonable. In order to procure this NSCLC medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Exkivity®?
Store the Capsules of Exkivity at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F).
What are the Highlights of prescribing information for Exkivity®?
Click Here to download full Exkivity prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.